Erratum: Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma (Journal of Thoracic Oncology (2017) 12(9) (1421–1433)(S1556086417304604)(10.1016/j.jtho.2017.05.024));Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma

Journal of Thoracic Oncology

Volumn 12, Issue 9, 2017, Pages 1421-1433

  Kao, Steven C ^a,b,c   Cheng, Yuen Yee ^a   Williams, Marissa ^a,c   Kirschner, Michaela B ^a,c   Madore, Jason ^c,d   Lum, Trina ^e   Sarun, Kadir H ^a   Linton, Anthony ^a,f   McCaughan, Brian ^c,g   Klebe, Sonja ^h   van Zandwijk, Nico ^a,c   Scolyer, Richard A ^c,e,f   Boyer, Michael J ^b,c   Cooper, Wendy A ^c,e,i   Reid, Glen ^a,c  

^a Asbestos Diseases Research Institute   (Australia)

^b Chris O'Brien Lifehouse ^*  (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d MELANOMA INSTITUTE AUSTRALIA   (Australia)

^e ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^f Department of Medical Oncology   (Australia)

^g Suite 304   (Australia)

^h FLINDERS MEDICAL CENTRE   (Australia)

ⁱ UNIVERSITY OF WESTERN SYDNEY   (Australia)

Author keywords

Malignant pleural mesothelioma; MicroRNA; PD L1; Prognosis

Indexed keywords

CISPLATIN; MICRORNA; MICRORNA 15A; MICRORNA 15B; MICRORNA 16; MICRORNA 193A 3P; MICRORNA 200C; PEMETREXED; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; CD274 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER CELL LINE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; DECORTICATION; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HAZARD RATIO; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN VITRO STUDY; LUCIFERASE ASSAY; LUNG CARCINOGENESIS; MAJOR CLINICAL STUDY; MALE; MET 5A CELL LINE; MSTO H211 CELL LINE; NCI-H28 CELL LINE; OVERALL SURVIVAL; PLEURA MESOTHELIOMA; PLEURECTOMY; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME; TISSUE MICROARRAY; TUMOR SUPPRESSOR GENE; VMC23 CELL LINE; BIOSYNTHESIS; GENETICS; LUNG TUMOR; MESOTHELIOMA; METABOLISM; PATHOLOGY; PLEURA TUMOR; PROGNOSIS; UPREGULATION;

AGED; B7-H1 ANTIGEN; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MICRORNAS; PLEURAL NEOPLASMS; PROGNOSIS; UP-REGULATION;

EID: 85025460505     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2017.11.005     Document Type: Erratum

References (60)

1. Vogelzang, N.J., Rusthoven, J.J., Symanowski, J., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21 (2003), 2636–2644.
2. Robinson BW MA, Lake, R.A., Malignant mesothelioma. Lancet 366 (2005), 397–408.
3. Linton, A., Pavlakis, N., O'Connell, R., et al. Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales. Br J Cancer 111 (2014), 1860–1869.
4. van Meerbeeck, J.P., Gaafar, R., Manegold, C., et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23 (2005), 6881–6889.
5. Zalcman, G., Mazieres, J., Margery, J., et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet 387 (2016), 1405–1414.
6. Matsuzaki, H., Maeda, M., Lee, S., et al. Asbestos-induced cellular and molecular alteration of immunocompetent cells and their relationship with chronic inflammation and carcinogenesis. J Biomed Biotechnol, 2012, 2012, 492608.
7. Linton, A., van Zandwijk, N., Reid, G., Clarke, S., Cao, C., Kao, S., Inflammation in malignant mesothelioma—friend or foe?. Ann Cardiothorac Surg 1 (2012), 516–522.
8. Schunselaar, L.M., Quispel-Janssen, J.M., Neefjes, J.J., Baas, P., A catalogue of treatment and technologies for malignant pleural mesothelioma. Expert Rev Anticancer Ther 16 (2016), 455–463.
9. Dong, H., Zhu, G., Tamada, K., Chen, L., B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 5 (1999), 1365–1369.
10. Fife, B., Bluestone, J., Control of peripheral T-cell tolerance and autoimmunity via CTLA-4 and PD-1 pathways. Immunol Rev 224 (2008), 166–182.
11. Creelan, B., Special report—update on immune checkpoint inhibitors in lung cancer. Cancer Control 21 (2014), 80–89.
12. Gee, G., Koestler, D., Christensen, B., et al. Downregulated microRNAs in the differential diagnosis of malignant pleural mesothelioma. Int J Cancer 127 (2010), 2859–2869.
13. Topalian, S.L., Hodi, F., Brahmer, J., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366 (2012), 2443–2454.
14. Brahmer, J., Tykodi, S., Chow, L., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366 (2012), 2455–2465.
15. Alley, E.M., Molife, L.R., Santoro, A., et al. Clinical safety and efficacy of pembrolizumab (MK-3475) in patients with malignant pleural mesothelioma: preliminary results from KEYNOTE-028 [abstract]. Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18–22; Philadelphia, PA, 2015, AACR, Philadelphia (PA), CT103.
16. Liu, J., Hamrouni, A., Wolowiec, D., et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 110 (2007), 296–304.
17. Qian, Y., Deng, J., Geng, L., et al. TLR4 signaling induces B7-H1 expression through MAPK pathways in bladder cancer cells. Cancer Invest 26 (2008), 816–821.
18. Lee, S.J., Jang, B.C., Lee, S.W., et al. Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274). FEBS Lett 580 (2006), 755–762.
19. Gowrishankar, K., Gunatilake, D., Gallagher, S.J., Tiffen, J., Rizos, H., Hesey, P., Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-kappaB. PLoS One, 10, 2015, e0123410.
20. Jiang, X., Zhou, J., Giobbie-Hurder, A., Wargo, J., Hodi, F.S., The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin Cancer Res 19 (2013), 598–609.
21. Kharma, B., Baba, T., Matsumura, N., et al. STAT1 drives tumor progression in serous papillary endometrial cancer. Cancer Res 74 (2014), 6519–6530.
22. Ota, K., Azuma, K., Kawahara, A., et al. Induction of PD-L1 expression by the EML4-ALK oncoprotein and downstream signaling pathways in non-small cell lung cancer. Clin Cancer Res 21 (2015), 4014–4021.
23. Lin, K., Cheng, J., Yang, T., Li, Y., Zhu, B., EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-kappaB. Biochem Biophys Res Commun 463 (2015), 95–101.
24. Ivanova, A.V., Ivanov, S.V., Prudkin, L., et al. Mechanisms of FUS1/TUSC2 deficiency in mesothelioma and its tumorigenic transcriptional effects. Mol Cancer, 8, 2009, 91.
25. Kettunen, E., Vivo, C., Gattacceca, F., Knuutila, S., Jaurand, M.C., Gene expression profiles in human mesothelioma cell lines in response to interferon-gamma treatment. Cancer Genet Cytogenet 152 (2004), 42–51.
26. Wang, W., Sun, J., Li, F., et al. A frequent somatic mutation in CD274 3′-UTR leads to protein over-expression in gastric cancer by disrupting miR-570 binding. Hum Mutat 33 (2012), 480–484.
27. Chen, L., Gibbons, D., Goswami, S., et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Comm, 5, 2014, 5241.
28. Cortez, M.A., Ivan, C., Valdecanas, D., et al. PDL1 Regulation by p53 via miR-34. J Natl Cancer Inst, 2016, 108.
29. Cedres, S., Ponce-Aix, S., Zugazagoitia, J., et al. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). PLoS One, 10, 2015, e0121071.
30. Mansfield, A.S., Roden, A.C., Peikert, T., et al. B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. J Thorac Oncol 9 (2014), 1036–1040.
31. Linton, A., Cheng, Y., Griggs, K., et al. An RNAi-based screen reveals PKL1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma. Br J Cancer 110 (2014), 510–519.
32. Travis, W.D., Brambilla, E., Müller-Hermelink, H.K., Harris, C.C., (eds.) World Health Organisation Classification of Tumours of the Lung, Pleura, Thymus and Heart, 2004, IARC, Lyon, France.
33. Kao, S., Lee, K., Armstrong, N., et al. Validation of tissue microarray technology in malignant pleural mesotheloma. Pathology 43 (2011), 128–132.
34. Mansfield, A., Roden, A., Peikert, T., et al. B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. J Thorac Oncol 9 (2014), 1036–1040.
35. Kirschner, M., Cheng, Y., Armstrong, N., et al. MiR-Score: a novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma. Mol Oncol 9 (2015), 715–726.
36. Kirschner, M., Cheng, Y., Badrian, B., et al. Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma. J Thorac Oncol 7 (2012), 1184–1191.
37. Reid, G., Pel, M., Kirschner, M., et al. Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma. Ann Oncol 24 (2013), 3128–3135.
38. Kryeziu, K., Jungwirth, U., Hoda, M.A., et al. Synergistic anticancer activity of arsenic trioxide with erlotinib is based on inhibition of EGFR-mediated DNA double-strand break repair. Mol Cancer Ther 12 (2013), 1073–1084.
39. Reid, G., Wallant, N.C., Patel, R., et al. Potent subunit-specific effects on cell growth and drug sensitivity from optimised siRNA-mediated silencing of ribonucleotide reductase. J RNAi Gene Silencing 5 (2009), 321–330.
40. Williams, M., Kirschner, M.B., Cheng, Y.Y., et al. miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma. Oncotarget 6 (2015), 23480–23495.
41. Livak, K.J., Schmittgen, T.D., Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25 (2001), 402–408.
42. Birnie, K.A., Yip, Y.Y., Ng, D.C., et al. Loss of miR-223 and JNK signaling contribute to elevated stathmin in malignant pleural mesothelioma. Mol Cancer Res 13 (2015), 1106–1118.
43. Fan, M., Krutilina, R., Sun, J., et al. Comprehensive analysis of microRNA (miRNA) targets in breast cancer cells. J Biol Chem 288 (2013), 27480–27493.
44. Agarwal, V., Bell, G.W., Nam, J.W., Bartel, D.P., Predicting effective microRNA target sites in mammalian mRNAs. Elife, 2015, 4.
45. Cedres S, Ponce Aix S, Zugazagoitia J, et al. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). Abstract presented at: 2014 European Society for Medical Oncology Congress. September 26-30, 2014; Madrid, Spain.
46. Cortese, J.F., Gowda, A.L., Wali, A., Eliason, J.F., Pass, H.I., Everson, R.B., Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma. Int J Cancer 118 (2006), 521–522.
47. Varesano, S., Leo, C., Boccardo, S., et al. Status of anaplastic lymphoma kinase (ALK) in malignant mesothelioma. Anticancer Res 34 (2014), 2589–2592.
48. Fassina, A., Cappellesso, R., Guzzardo, V., et al. Epithelial-mesenchymal transition in malignant mesothelioma. Mod Path 25 (2012), 86–99.
49. Polytarchou, C., Iliopoulos, D., Struhl, K., An integrated transcriptional regulatory circuit that reinforces the breast cancer stem cell state. Proc Natl Acad Sci U S A 109 (2012), 14470–14475.
50. van den Beucken, T., Koch, E., Chu, K., et al. Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER. Nat Comm, 5, 2014, 5203.
51. Jia, X., Li, X., Shen, Y., et al. MiR-16 regulates mouse peritoneal macrophage polarization and affects T-cell activation. J Cell Mol Med 20 (2016), 1898–1907.
52. Bueno, R., Stawiski, E.W., Goldstein, L.D., et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet 48 (2016), 407–416.
53. Kubo, T., Toyooka, S., Tsukuda, K., et al. Epigenetic silencing of microRNA-34b/c plays an important role in the pathogenesis of malignant pleural mesothelioma. Clin Cancer Res 17 (2011), 4965–4974.
54. Wrangle, J., Wang, W., Koch, A., et al. Alterations of immune response of non-small cell lung cancer with azacytidine. Oncotarget 4 (2013), 2067–2079.
55. Brennecke, J., Stark, A., Russell, R.B., Cohen, S.M., Principles of microRNA-target recognition. PLoS Biol, 3, 2005, e85.
56. Bartel, D.P., MicroRNAs: target recognition and regulatory functions. Cell 136 (2009), 215–233.
57. Li, Y., Gao, L., Luo, X., Wang, L., Gao, X., Wang, W., et al. Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway. Blood 121 (2013), 499–509.
58. Xu, C., Fillmore, C.M., Koyama, S., et al. Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. Cancer Cell 25 (2014), 590–604.
59. Opitz, I., Soltermann, A., Abaecherli, M., et al. PTEN expression is a strong predictor of survival in mesothelioma patients. Eur J Cardiothoracic Surg 33 (2008), 502–506.
60. Kao, S.C., Fulham, M., Wong, K., et al. A significant metabolic and radiological response after a novel targeted microRNA-based treatment approach in malignant pleural mesothelioma. Am J Respir Crit Care Med 191 (2015), 1467–1469.